Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: rituximab [MabThera/Rituxan]
Drug: Methotrexate
Drug: Cytarabine

First Posted Date: 2007-08-17

Last Posted Date: 2014-08-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 5

Registration Number: NCT00517699

Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Drug: cytarabine

First Posted Date: 2007-08-15

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 21

Registration Number: NCT00516828

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
McGill University - Dept. Oncology, Montreal, Quebec, Canada

and more 1 locations

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

Not Applicable

Withdrawn

Conditions: Lymphoma

First Posted Date: 2007-08-08

Last Posted Date: 2016-12-15

Lead Sponsor: University of Miami

Registration Number: NCT00513188

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: AMD3100
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2007-08-07

Last Posted Date: 2016-12-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 52

Registration Number: NCT00512252

Locations: 🇺🇸
Washington University, St. Louis, Missouri, United States

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Campath-1H
Drug: G-CSF
Drug: GM-CSF
Drug: BCNU
Drug: Stem Cell Transplant
Drug: Preparative Regimen for Allogenic Stem Cell Transplantation
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Campath
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Low dose total body irradiation

First Posted Date: 2007-07-25

Last Posted Date: 2011-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00505921

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2007-07-23

Last Posted Date: 2010-09-24

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 36

Registration Number: NCT00505700

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel/ Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Biological: filgrastim
Drug: clofarabine
Drug: cytarabine
Genetic: microarray analysis
Procedure: biopsy

First Posted Date: 2007-07-19

Last Posted Date: 2023-09-18

Lead Sponsor: University of Nebraska

Target Recruit Count: 2

Registration Number: NCT00503880

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Recruiting

Conditions: T Acute Lymphoblastic Leukemia
T Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Nelarabine
Drug: Pegaspargase
Drug: Prednisone
Drug: Venetoclax
Drug: Vincristine Sulfate

First Posted Date: 2007-07-16

Last Posted Date: 2024-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 160

Registration Number: NCT00501826

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Phase 3

Conditions: Diffuse Large B-Cell Lymphoma
IPI≥2

Interventions: Drug: Rituximab
Drug: Vincristina
Drug: Ciclofosfamide
Drug: Prednisone
Drug: Doxorubicina
Drug: Pegfilgrastim
Drug: Mitoxantrone
Drug: ARA-C
Drug: Lenograstim
Drug: BCNU
Drug: VP-16
Procedure: ASCT

First Posted Date: 2007-07-11

Last Posted Date: 2011-02-15

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 399

Registration Number: NCT00499018

Locations: 🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹
Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy
🇮🇹
Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

and more 71 locations

A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)

Phase 3

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: cytosine arabinoside

First Posted Date: 2007-07-03

Last Posted Date: 2016-03-31

Lead Sponsor: Northern Italy Leukemia Group

Target Recruit Count: 573

Registration Number: NCT00495287

Locations: 🇮🇹
Istituti Ospitalieri, Cremona, Italy
🇮🇹
S.C. Ematologia - Azienda Ospedaliera S.Croce e Carle, Cuneo, CN, Italy
🇮🇹
Ematologia - AOU Careggi, Firenze, FI, Italy

and more 14 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy